The promise of TRAIL—potential and risks of a novel anticancer therapy

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising new anticancer biotherapeutic. As shown by many preclinical studies, TRAIL efficiently induces apoptosis in numerous tumor cell lines but not in the majority of normal cells. However, an increasing number of publications report on a predominance of TRAIL resistance in primary human tumor cells, which require sensitization for TRAIL-induced apoptosis. Sensitization of cancer cells by treatment with chemotherapeutic drugs and irradiation has been shown to restore TRAIL sensitivity in many TRAIL-resistant tumor cells. Accordingly TRAIL treatment has been successfully used in different in vivo models for the treatment of tumors also in combination with chemotherapeutics without significant toxicity. However, some reports demonstrated toxicity of TRAIL alone or in combination with chemotherapeutic drugs in normal cells. This review summarizes data concerning the apoptosis-inducing pathways and efficacy of TRAIL, alone or in combination with chemotherapeutic drugs, in primary cancer cells compared to the unwanted effects of TRAIL treatment on normal tissue. We discuss the different in vitro tumor cell models and the potential of different recombinant forms of TRAIL or agonistic antibodies to TRAIL death receptors. Most preclinical studies show a high efficiency of a combinatorial TRAIL-based therapy in animal models and in primary human ex vivo tumor cells with a low toxicity in normal cells. Accordingly clinical phase I/II studies have begun and will be developed further with caution.

[1]  A. Grandien,et al.  High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. , 2003, Anticancer research.

[2]  B. Sipos,et al.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.

[3]  A. Evdokiou,et al.  Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. , 2002, Bone.

[4]  G. Cohen,et al.  Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.

[5]  C. Ware,et al.  Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2 , 2005, Clinical Cancer Research.

[6]  M. Gregor,et al.  HDAC inhibitor treatment of hepatoma cells induces both TRAIL‐independent apoptosis and restoration of sensitivity to TRAIL , 2006, Hepatology.

[7]  B. Nickoloff,et al.  Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations , 2002, Experimental dermatology.

[8]  G. Gores,et al.  Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[9]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[10]  Lifen Gao,et al.  Hepatitis B Virus Sensitizes Hepatocytes to TRAIL-Induced Apoptosis through Bax1 , 2007, The Journal of Immunology.

[11]  D. Schrump,et al.  The Essential Role of the Mitochondria‐Dependent Death‐Signaling Cascade in Chemotherapy‐Induced Potentiation of Apo2L/TRAIL Cytotoxicity in Cultured Thoracic Cancer Cells: Amplified Caspase 8 Is Indispensable for Combination‐Mediated Massive Cell Death , 2006, Cancer journal.

[12]  E. Bröcker,et al.  Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation , 2003, Molecular and Cellular Biology.

[13]  B. Kroesen,et al.  Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR* , 2005, Journal of Biological Chemistry.

[14]  A. Kraft,et al.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells , 2002, Oncogene.

[15]  H. Xin,et al.  Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. , 2006, Cancer research.

[16]  T. Burns,et al.  The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. , 2000, Cancer research.

[17]  A. Teufel,et al.  Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. , 2006, Oncology reports.

[18]  E. D. de Vries,et al.  The clinical trail of TRAIL. , 2006, European journal of cancer.

[19]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[20]  H. Walczak,et al.  Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 , 2004, International journal of cancer.

[21]  M. Smyth,et al.  TRAIL and its receptors as targets for cancer therapy , 2004, Cancer science.

[22]  Wafik S El-Deiry,et al.  Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.

[23]  M. Andreeff,et al.  Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies , 1997, British journal of haematology.

[24]  N. Hou,et al.  Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. , 2007, Biochemical and biophysical research communications.

[25]  P. Scheurich,et al.  TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.

[26]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[27]  J. Jelinek,et al.  TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors , 2002, Leukemia.

[28]  B. Kroesen,et al.  Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. , 2004, Neoplasia.

[29]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[30]  P. Smolewski,et al.  The inhibitor of apoptosis protein family and its antagonists in acute leukemias , 2004, Apoptosis.

[31]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[32]  S. Inoue,et al.  Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.

[33]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[34]  P. Secchiero,et al.  TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. , 2004, Current pharmaceutical design.

[35]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[36]  A. Evdokiou,et al.  Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis , 2002, International journal of cancer.

[37]  E. Bröcker,et al.  Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.

[38]  P. Marks,et al.  Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.

[39]  G. Cohen,et al.  Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis , 2006, Cell Death and Differentiation.

[40]  A. Österborg,et al.  Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D , 2001, Leukemia.

[41]  P. Hersey,et al.  Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types , 2000, FEBS letters.

[42]  U. Jaeger,et al.  Expression of tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) receptors and sensitivity to TRAIL‐induced apoptosis in primary B‐cell acute lymphoblastic leukaemia cells , 2000, British journal of haematology.

[43]  T. Sayers,et al.  Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy , 2004, The Journal of experimental medicine.

[44]  T. Sayers,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. , 2003, Cancer research.

[45]  F. Ballet,et al.  Isolation, Culture and Characterization of Adult Human Hepatocytes from Surgical Liver Biopsies , 1984, Hepatology.

[46]  A. Evdokiou,et al.  Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail , 2001, Journal of orthopaedic surgery.

[47]  I. Ishida,et al.  Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2 , 2004, Cell Death and Differentiation.

[48]  J. Hsieh,et al.  Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.

[49]  H. Hondermarck,et al.  Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). , 2004, Experimental cell research.

[50]  Robin Foà,et al.  TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. , 2005, Haematologica.

[51]  William E Grizzle,et al.  Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  I. Bechmann,et al.  Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.

[53]  P. Krammer,et al.  c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[54]  F. Beguinot,et al.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma Cells* , 2002, The Journal of Biological Chemistry.

[55]  V. Yong,et al.  Human Astrocytes Are Resistant to Fas Ligand and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis , 2006, The Journal of Neuroscience.

[56]  P. Möller,et al.  TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. , 2002, Gastroenterology.

[57]  Z. Wang,et al.  TRAIL-R2 (DR5) Mediates Apoptosis of Synovial Fibroblasts in Rheumatoid Arthritis1 , 2003, The Journal of Immunology.

[58]  D. Tyrrell,et al.  TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice , 2004, Cancer Research.

[59]  C. Trautwein,et al.  Involvement of TRAIL and its receptors in viral hepatitis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  Ken Garber,et al.  New apoptosis drugs face critical test , 2005, Nature Biotechnology.

[61]  B. Nickoloff,et al.  Low‐dose UV‐radiation sensitizes keratinocytes to TRAIL‐induced apoptosis , 2004, Journal of cellular physiology.

[62]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[63]  J. Pober,et al.  TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells 1 , 2003, The Journal of Immunology.

[64]  Y. Rustum,et al.  Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. , 2002, Cancer research.

[65]  O. Ogawa,et al.  TRAIL and chemotherapeutic drugs in cancer therapy. , 2004, Vitamins and hormones.

[66]  P. Secchiero,et al.  Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)--mediated cytotoxicity by selective up-regulation of TRAIL-R1. , 2001, Blood.

[67]  A. Thorburn,et al.  Death receptor-induced cell killing. , 2004, Cellular signalling.

[68]  G. Gores,et al.  Activated stellate cells express the TRAIL receptor‐2/death receptor‐5 and undergo TRAIL‐mediated apoptosis , 2003, Hepatology.

[69]  M. Berger,et al.  mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells , 2005, Molecular and Cellular Biology.

[70]  T. Luger,et al.  Interleukin-1 Protects Transformed Keratinocytes from Tumor Necrosis Factor-related Apoptosis-inducing Ligand* , 1998, The Journal of Biological Chemistry.

[71]  John Calvin Reed,et al.  FLIP protein and TRAIL-induced apoptosis. , 2004, Vitamins and hormones.

[72]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[73]  D. Zink,et al.  Hepatocyte growth factor induces Mcl‐1 in primary human hepatocytes and inhibits CD95‐mediated apoptosis via Akt , 2004, Hepatology.

[74]  M. Li‐Weber,et al.  Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL , 2005, Hepatology.

[75]  H. Nishiyama,et al.  Enhancement of TRAIL/Apo2L‐mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells , 2003, International journal of cancer.

[76]  B. Hylander,et al.  The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice , 2005, Journal of Translational Medicine.

[77]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[78]  B. Nickoloff,et al.  Avoiding premature apoptosis of normal epidermal cells , 2001, Nature Medicine.

[79]  H. Wajant,et al.  Tumor therapeutics by design: targeting and activation of death receptors. , 2005, Cytokine & growth factor reviews.

[80]  N. Müller,et al.  A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95 , 2006, Journal of Molecular Medicine.

[81]  T. Lehnert,et al.  Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  L. Sedger,et al.  Characterization of the in vivo function of TNF‐α‐related apoptosis‐inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene‐deficient mice , 2002, European journal of immunology.

[83]  G. Cohen,et al.  TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.

[84]  E. D. de Vries,et al.  TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas , 2006, Clinical Cancer Research.

[85]  D. Rimm,et al.  Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer , 2005, Clinical Cancer Research.

[86]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[87]  N. Munshi,et al.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. , 2002, Blood.

[88]  M. Manns,et al.  Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake , 2005, Gut.

[89]  A. Kolb,et al.  TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window , 2007, Hepatology.

[90]  B. Kroesen,et al.  Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. , 2005, Cancer research.

[91]  M. Fiscella,et al.  HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo , 2005, British Journal of Cancer.

[92]  T. Giordano,et al.  Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells , 2002, Cell Death and Differentiation.

[93]  Is TRAIL hepatotoxic? , 2001, Hepatology.

[94]  T. Griffith,et al.  Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. , 2006, Journal of pediatric surgery.

[95]  T. Sayers,et al.  TNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer , 2006, Immunology and cell biology.

[96]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[97]  W. Winkelmann,et al.  Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells , 2003, International journal of cancer.

[98]  T. Griffith,et al.  Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression , 2005, Cancer biology & therapy.

[99]  M. Smyth,et al.  Eradication of established tumors in mice by a combination antibody-based therapy , 2006, Nature Medicine.

[100]  P. Schneider,et al.  Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. , 2000, Methods in enzymology.

[101]  Henning Walczak,et al.  The interplay between the Bcl-2 family and death receptor-mediated apoptosis. , 2004, Biochimica et biophysica acta.

[102]  Erwin G. Van Meir,et al.  Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. , 2001, Cancer research.

[103]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[104]  S. Shankar,et al.  HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.

[105]  I. Bechmann,et al.  Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate , 2005, Journal of Neuroimmunology.

[106]  H. Koeppen,et al.  Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.

[107]  R. Kimberly,et al.  Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway , 2003, Oncogene.

[108]  T. Shiraishi,et al.  Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells , 2004, Oncogene.

[109]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[110]  P. Lu,et al.  In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL , 2006, Cancer Gene Therapy.

[111]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[112]  D. Buchsbaum,et al.  TRAIL receptor-targeted therapy. , 2006, Future oncology.

[113]  C. Voelkel-Johnson.  An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but not Normal Prostate Cells , 2003, Cancer biology & therapy.

[114]  Y. Gazitt.  TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells , 1999, Leukemia.

[115]  Lin Chen,et al.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.

[116]  J. Schalkwijk,et al.  Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. , 2003, The Journal of investigative dermatology.

[117]  G. Cohen,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.

[118]  M L Yarmush,et al.  Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation , 1992, The Journal of cell biology.

[119]  C. Smith,et al.  Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.

[120]  M. Herlyn,et al.  Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells* , 2004, Journal of Biological Chemistry.

[121]  W. El-Deiry,et al.  The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. , 2006, Cancer journal.

[122]  T. Sayers,et al.  Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy , 2005, Cancer Immunology, Immunotherapy.

[123]  A. Ashkenazi,et al.  Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.

[124]  O. Ogawa,et al.  Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. , 2002, International journal of oncology.

[125]  W. Stremmel,et al.  Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs , 2004, Cell Death and Differentiation.